186 related articles for article (PubMed ID: 24312671)
21. Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies.
Papakostas GI; Cooper-Kazaz R; Appelhof BC; Posternak MA; Johnson DP; Klibanski A; Lerer B; Fava M
Int Clin Psychopharmacol; 2009 Jan; 24(1):19-25. PubMed ID: 19092448
[TBL] [Abstract][Full Text] [Related]
22. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
Hjalmarsson L; Corcos M; Jeammet P
Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
[TBL] [Abstract][Full Text] [Related]
23. Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram.
Jacobsen PL; Nomikos GG; Zhong W; Cutler AJ; Affinito J; Clayton A
CNS Spectr; 2020 Feb; 25(1):50-63. PubMed ID: 31010445
[TBL] [Abstract][Full Text] [Related]
24. Apathy in currently nondepressed patients treated with a SSRI for a major depressive episode: outcomes following randomized switch to either duloxetine or escitalopram.
Raskin J; George T; Granger RE; Hussain N; Zhao GW; Marangell LB
J Psychiatr Res; 2012 May; 46(5):667-74. PubMed ID: 22410206
[TBL] [Abstract][Full Text] [Related]
25. Serum cholesterol and serotonergic function in major depressive disorder.
Papakostas GI; Petersen T; Mischoulon D; Hughes ME; Alpert JE; Nierenberg AA; Rosenbaum JF; Fava M
Psychiatry Res; 2003 May; 118(2):137-45. PubMed ID: 12798978
[TBL] [Abstract][Full Text] [Related]
26. Plasma serotonin levels are associated with antidepressant response to SSRIs.
Holck A; Wolkowitz OM; Mellon SH; Reus VI; Nelson JC; Westrin Å; Lindqvist D
J Affect Disord; 2019 May; 250():65-70. PubMed ID: 30831543
[TBL] [Abstract][Full Text] [Related]
27. Sexual function and depressive symptoms in young women with elevated macroprolactin content: a pilot study.
Krysiak R; Drosdzol-Cop A; Skrzypulec-Plinta V; Okopien B
Endocrine; 2016 Jul; 53(1):291-8. PubMed ID: 26902871
[TBL] [Abstract][Full Text] [Related]
28. Depression impairs learning, whereas the selective serotonin reuptake inhibitor, paroxetine, impairs generalization in patients with major depressive disorder.
Herzallah MM; Moustafa AA; Natsheh JY; Danoun OA; Simon JR; Tayem YI; Sehwail MA; Amleh I; Bannoura I; Petrides G; Myers CE; Gluck MA
J Affect Disord; 2013 Nov; 151(2):484-492. PubMed ID: 23953023
[TBL] [Abstract][Full Text] [Related]
29. Effects of selective serotonin reuptake inhibitor treatment on plasma oxytocin and cortisol in major depressive disorder.
Keating C; Dawood T; Barton DA; Lambert GW; Tilbrook AJ
BMC Psychiatry; 2013 Apr; 13():124. PubMed ID: 23627666
[TBL] [Abstract][Full Text] [Related]
30. Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy.
Leo R; Di Lorenzo G; Tesauro M; Razzini C; Forleo GB; Chiricolo G; Cola C; Zanasi M; Troisi A; Siracusano A; Lauro R; Romeo F
J Clin Psychiatry; 2006 Nov; 67(11):1760-6. PubMed ID: 17196057
[TBL] [Abstract][Full Text] [Related]
31. Antidepressant therapy and C-reactive protein levels.
O'Brien SM; Scott LV; Dinan TG
Br J Psychiatry; 2006 May; 188():449-52. PubMed ID: 16648531
[TBL] [Abstract][Full Text] [Related]
32. Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: outcome after long-term follow-up.
Peselow ED; Tobia G; Karamians R; Pizano D; IsHak WW
Psychiatry Res; 2015 Feb; 225(3):680-6. PubMed ID: 25496869
[TBL] [Abstract][Full Text] [Related]
33. [Prevalence of macroprolactinemia among 115 patients with hyperprolactinemia].
Vilar L; Moura E; Canadas V; Gusmão A; Campos R; Leal E; Teixeira L; Santos V; Gomes B; Lima M; Paiva R; Albuquerque JL; Egito CS; Botelho CA; Azevedo M; Casulari LA; Naves LA
Arq Bras Endocrinol Metabol; 2007 Feb; 51(1):86-91. PubMed ID: 17435860
[TBL] [Abstract][Full Text] [Related]
34. Sertraline: a review of its use in the management of major depressive disorder in elderly patients.
Muijsers RB; Plosker GL; Noble S
Drugs Aging; 2002; 19(5):377-92. PubMed ID: 12093324
[TBL] [Abstract][Full Text] [Related]
35. Cardiometabolic Risk Factors in Men with Elevated Macroprolactin Content: A Pilot Study.
Krysiak R; Szkróbka W; Okopień B
Exp Clin Endocrinol Diabetes; 2021 Jan; 129(1):7-13. PubMed ID: 31185509
[TBL] [Abstract][Full Text] [Related]
36. [Macroprolactinemia in the differential diagnosis of hyperprolactinemia].
Toldy E; Löcsei Z; Szabolcs I; Kneffel P; Góth M; Szöke D; Kovács LG
Orv Hetil; 2003 Oct; 144(43):2121-7. PubMed ID: 14661444
[TBL] [Abstract][Full Text] [Related]
37. Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.
Ball SG; Ferguson MB; Martinez JM; Pangallo BA; Nery ES; Dellva MA; Sparks J; Zhang Q; Liu P; Bangs M; Goldberger C
J Clin Psychiatry; 2016 May; 77(5):635-42. PubMed ID: 27035159
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy of selective serotonin reuptake inhibitors (SSRI) in treating major depressive disorder: a protocol for network meta-analysis of randomised controlled trials.
Jia Y; Zhu H; Leung SW
BMJ Open; 2016 Jun; 6(6):e010142. PubMed ID: 27267106
[TBL] [Abstract][Full Text] [Related]
39. A case with euprolactinemic galactorrhea induced by escitalopram.
Gulsun M; Algul A; Semiz UB; Ates MA; Doruk A; Ebrinc S; Basoglu C; Cetin M
Int J Psychiatry Med; 2007; 37(3):275-8. PubMed ID: 18314855
[TBL] [Abstract][Full Text] [Related]
40. Serum prolactin and macroprolactin levels in diabetic nephropathy.
Sari F; Sari R; Ozdem S; Sarikaya M; Cetinkaya R
Clin Nephrol; 2012 Jul; 78(1):33-9. PubMed ID: 22732335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
